LU88475I2 - Didanosine (Videx) - Google Patents

Didanosine (Videx)

Info

Publication number
LU88475I2
LU88475I2 LU88475C LU88475C LU88475I2 LU 88475 I2 LU88475 I2 LU 88475I2 LU 88475 C LU88475 C LU 88475C LU 88475 C LU88475 C LU 88475C LU 88475 I2 LU88475 I2 LU 88475I2
Authority
LU
Luxembourg
Prior art keywords
videx
didanosine
virus
dideoxyguanosine
dideoxyadenosine
Prior art date
Application number
LU88475C
Other languages
English (en)
Original Assignee
Us Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25084165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88475(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Commerce filed Critical Us Commerce
Publication of LU88475I2 publication Critical patent/LU88475I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
LU88475C 1985-08-26 1994-04-13 Didanosine (Videx) LU88475I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76901685A 1985-08-26 1985-08-26

Publications (1)

Publication Number Publication Date
LU88475I2 true LU88475I2 (fr) 1994-09-09

Family

ID=25084165

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88475C LU88475I2 (fr) 1985-08-26 1994-04-13 Didanosine (Videx)

Country Status (16)

Country Link
US (1) US4861759A (fr)
EP (1) EP0216510B1 (fr)
JP (1) JPS62501712A (fr)
AT (1) ATE96325T1 (fr)
AU (1) AU570853B2 (fr)
CA (1) CA1269044A (fr)
CY (1) CY1792A (fr)
DE (1) DE3689220T2 (fr)
HK (1) HK47694A (fr)
IE (1) IE64518B1 (fr)
IL (1) IL79700A (fr)
LU (1) LU88475I2 (fr)
MX (1) MX9203377A (fr)
NL (1) NL940005I2 (fr)
NZ (1) NZ217185A (fr)
WO (1) WO1987001284A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8512330D0 (en) * 1985-05-15 1985-06-19 Wellcome Found Antiviral compounds
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
IL86009A (en) * 1987-04-10 1991-09-16 Us Health Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US5495010A (en) * 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
JP2648329B2 (ja) * 1987-09-18 1997-08-27 エフ・ホフマン−ラ ロシュ アーゲー エイズの予防または治療用医薬組成物
US5028595A (en) * 1987-09-18 1991-07-02 Hoffmann-La Roche Inc. Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus
GB8800276D0 (en) * 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
EP0374096B1 (fr) * 1988-12-14 1992-12-02 Ciba-Geigy Ag Thérapie combinée utilisant le 2',5'-didéoxypurine nucléoside et inhibiteur de purine nucléoside-phosphorylase et ses compositions
IL93682A (en) * 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
NZ232912A (en) * 1989-03-17 1992-06-25 Oncogen Ltd Lp Synergistic composition of nucleoside derivatives for inhibiting hiv
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
US5571839A (en) * 1989-04-28 1996-11-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) D-aspartic acid β-hydroxamate for the treatment of viral infections and tumors
FI95269C (fi) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja
AU5832990A (en) * 1989-05-15 1990-12-18 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method of treatment of hepatitis
US6207650B1 (en) * 1989-05-15 2001-03-27 Bristol-Myers Squibb Company Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5268389A (en) * 1989-10-16 1993-12-07 Uniroyal Chemical Company, Inc. Thiocarboxylate ester compounds compositions containing the same
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6642245B1 (en) * 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5221611A (en) * 1991-06-19 1993-06-22 Sigma Chemical Company Ddi immunoassays, derivatives, conjugates and antibodies
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
US5231174A (en) * 1992-02-27 1993-07-27 University Of Iowa Research Foundation 2'isodideoxy-β-D-nucleosides as stable antiviral agents
US6429208B1 (en) * 1992-03-27 2002-08-06 Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
AU685128B2 (en) * 1993-05-21 1998-01-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995007086A1 (fr) * 1993-09-10 1995-03-16 Emory University Nucleosides a activite contre le virus de l'hepatite b
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
WO1995017875A2 (fr) * 1993-12-20 1995-07-06 Compagnie De Developpement Aguettant MELANGES DE DIDESOXY-NUCLEOSIDES ET DE β-HYDROXAMATE DE L'ACIDE D-ASPARTIQUE UTILISE DANS L'INHIBITION DE LA PROPAGATION D'UN RETROVIRUS
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5705522A (en) * 1995-09-15 1998-01-06 Compagnie De Developpement Aguettant S.A. Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors
CA2189097A1 (fr) 1995-11-15 1997-05-16 Pin-Fang Lin Composition et methode pour le traitement de l'infection retrovirale
US5728560A (en) * 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6369237B1 (en) 1997-03-07 2002-04-09 President And Fellows Of Harvard College DNA glycosylase inhibitors, and uses related thereto
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
JP2000136136A (ja) * 1998-10-30 2000-05-16 Fujirebio Inc 抗ウイルス剤
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
CA2270600A1 (fr) 1999-05-03 2000-11-03 Infectio Recherche Inc. Methode et preparations pour le traitement de maladies, en particulier de celles causees par le virus de l'immunodeficience humaine et leishmania
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
RU2172632C1 (ru) * 2000-12-01 2001-08-27 Каплина Элли Николаевна Способ получения иммунотропного противовирусного препарата
EP2316469A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
PL1778251T3 (pl) 2004-07-27 2011-09-30 Gilead Sciences Inc Koniugaty fosfonianowo-nukleozydowe jako środki przeciw wirusowi HIV
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
WO2016001907A1 (fr) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
ES2930667T3 (es) 2014-07-11 2022-12-21 Gilead Sciences Inc Moduladores de receptores de tipo Toll para el tratamiento de VIH
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081534A (en) * 1973-09-11 1978-03-28 Burroughs Wellcome Co. Amino purine nucleosides as autoimmune suppressant agents
US4112221A (en) * 1974-07-17 1978-09-05 Asahi Kasei Kogyo Kabushiki Kaisha Process for preparing 8,2'-O-anhydropurine nucleosides
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
JPS59104399A (ja) * 1982-12-03 1984-06-16 Takeda Chem Ind Ltd ヌクレオチドおよびヌクレオシドの相互分離方法
ATE108794T1 (de) * 1985-05-15 1994-08-15 Wellcome Found Therapeutische nucleoside und deren herstellung.

Also Published As

Publication number Publication date
EP0216510A2 (fr) 1987-04-01
IL79700A (en) 1991-09-16
JPS62501712A (ja) 1987-07-09
HK47694A (en) 1994-05-20
IE940570L (en) 1987-02-26
AU570853B2 (en) 1988-03-24
NL940005I2 (nl) 1999-08-02
WO1987001284A1 (fr) 1987-03-12
CA1269044A (fr) 1990-05-15
IE862265L (en) 1987-02-26
EP0216510B1 (fr) 1993-10-27
NZ217185A (en) 1990-03-27
DE3689220T2 (de) 1994-02-24
ATE96325T1 (de) 1993-11-15
DE3689220D1 (de) 1993-12-02
US4861759A (en) 1989-08-29
NL940005I1 (nl) 1994-05-16
CY1792A (en) 1995-10-20
AU6196886A (en) 1987-03-24
MX9203377A (es) 1992-09-01
JPH0215523B2 (fr) 1990-04-12
IE64518B1 (en) 1995-08-09
EP0216510A3 (en) 1989-08-02
IL79700A0 (en) 1986-11-30

Similar Documents

Publication Publication Date Title
LU88475I2 (fr) Didanosine (Videx)
BR8505525A (pt) Processo de remocao de vapor eletrolito
DE3671175D1 (de) Kuehlung von hohlfaser-kreuzstrom-separatoren.
NO166040C (no) Fremgangsmaate ved oxyanion-katalysert polymerisering av en eller flere polare alfa-olefinmonomerer av acryltypen.
DE3674477D1 (de) Reaktiv-ion-aetzungsverfahren.
IL79699A (en) Antiviral compositions containing 2',3'-dideoxycytidine or its mono-or triphosphate
FI870170A0 (fi) Vaermestabila finfoerdelade artificiella soetningsmedel.
DE3664910D1 (de) Substituted 2,3,4,9-tetrahydro-1h-carbazole-1-acetic acid derivatives
BR8601180A (pt) Processo para controlar a adicao de a1f3 a um eletrolito
DE3687059D1 (de) Herstellung einer fluessigmetallionenquelle.
IT1131182B (it) Processo di preparazione di n-di-n-propil-2,6-dinitro-4-trifluorometilanilina a basso contenuto di nitrosammine
IT8520453A0 (it) Analoghi di ossa prostaglandina 7-ossabicicloeptano sostituiti.!
DK162095C (da) Fremgangsmaade til fremstilling af thiotetronsyre
IT1193500B (it) Processo per la preparazione di 2,2'-bis/4-(1,1,3,3-tetrametilbutil) fenol/solfuro
SU691939A1 (ru) Контакт
DK163926C (da) 6-halogen- eller 6,6-dihalogen-1,1-dioxopenicillanoyloxy-methyl-6-oed-2-(2-alkoxycarbonyl-1-methylvinylamino- eller 1-methyl-3-oxo-1-butenylamino)-2-phenylacetamidoaapenicillanater
ATE75478T1 (de) Gametozide.
DE3569523D1 (de) N-(substituted-alkyl) dichloroacetamide derivatives
DE3678975D1 (de) Stabilisierung von entwickelten elektrophoregrammen.
IN156668B (fr)
ES549507A0 (es) Procedimiento de preparacion de 8-((4-(2-pirimidinil)-1-pi- perazinil)alquil)-8-azaspiro-(4,5)-decano-7,9-diona
ES549506A0 (es) Procedimiento de preparacion de 8-((4-(2-pirimidinil)-1-pi- perazinil)alquil)-8-azaspiro-(4,5)-decano-7,9-diona
ATA100484A (de) Sicherheits-gluehlampenfassung
KR850005760U (ko) 음이온 발생기
ATE65732T1 (de) Erzeugung von bauholz.